In a strategic move aimed at advancing cancer treatment in China, Senti Biosciences has entered into a collaboration with Celest Therapeutics (Shanghai) Co Ltd, a prominent biotechnology company based in China. The partnership is focused on the clinical development of SENTI-301A, a cutting-edge CAR-NK cell therapy derived from healthy donors, specifically designed to target GPC3-expressing tumors.
The announcement of this collaboration caused a meteoric rise in Senti Biosciences’ stock value, with a staggering surge of over 100% observed today.
At the time of this publication, Senti Biosciences Inc stock (SNTI) has witnessed a surge.
Senti Biosciences Inc
Current Price: $0.61
Change : +0.31
Change (%): (107.33%)
Volume: 57.3M
Source: Tomorrow Events Market Data
Under this collaboration, Celest Therapeutics will spearhead the clinical development, operations, and manufacturing processes of SENTI-301A, while receiving technical expertise and support from Senti Bio. Initial patient enrollment is scheduled to commence with a pilot trial in mainland China, with the first patient expected to be enrolled in the first half of 2024. Additionally, Celest and Senti Bio have the option to extend the clinical development of SENTI-301A to regions including Hong Kong, Macau, and Taiwan.
Senti Bio will maintain exclusive commercialization rights for SENTI-301A outside of mainland China, Hong Kong, Macau, and Taiwan.
As part of the collaboration agreement, Senti Bio stands to potentially receive up to $156 million in milestone payments, in addition to tiered royalty payments. The finer details of the transaction have not been disclosed.
The planned dose-finding trial will involve nine patients diagnosed with advanced glypican 3-expressing hepatocellular carcinoma (HCC), distributed across two dose cohorts. The trial will assess safety through meticulous monitoring of adverse events and dose-limiting toxicities. Furthermore, efficacy analyses will be conducted using standard response criteria tailored for liver cancer.
This strategic collaboration between Senti Biosciences and Celest Therapeutics marks a significant milestone in the pursuit of innovative cancer therapies, offering new hope for patients in China grappling with solid tumors. The partnership combines the strengths and expertise of both companies to accelerate the development and deployment of SENTI-301A, potentially revolutionizing the landscape of cancer treatment in the region.
